FBLG
FibroBiologics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.40
−5.72%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
+76.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 15, 2026 | Khoja Hamid · officer: Chief Scientific Officer | A-Award | 298,508 | $1.68 |
| Jun 23, 2026 | Hoffman Robert E. · director | A-Award | 30,803 | $0.75 |
| Jun 23, 2026 | Niklas Victoria Ninon Olivia · director | A-Award | 30,803 | $0.75 |
| Jun 23, 2026 | Link Matthew · director | A-Award | 30,803 | $0.75 |
| Jun 23, 2026 | Cilento Richard C. Jr. · director | A-Award | 30,803 | $0.75 |
| May 4, 2026 | Khoja Hamid · officer: Chief Scientific Officer | A-Award | 61,607 | $1.38 |
| May 4, 2026 | GARCIA RUBEN A · officer: General Counsel | A-Award | 61,607 | $1.38 |
| May 4, 2026 | Davis Jason · officer: Chief Financial Officer | A-Award | 61,607 | $1.38 |
| May 4, 2026 | O'HEERON PETE · director, officer: CHIEF EXECUTIVE OFFICER | A-Award | 92,410 | $1.38 |
| Mar 5, 2026 | Khoja Hamid · officer: Chief Scientific Officer | Purchase | 30,000 | $0.38 |
| Mar 4, 2026 | O'HEERON PETE · director, officer: CHIEF EXECUTIVE OFFICER | Purchase | 15,872 | $0.38 |
| Mar 4, 2026 | O'HEERON PETE · director, officer: CHIEF EXECUTIVE OFFICER | Purchase | 17,428 | $0.35 |
| Mar 4, 2026 | O'HEERON PETE · director, officer: CHIEF EXECUTIVE OFFICER | Purchase | 18,200 | $0.41 |
| Mar 2, 2026 | GARCIA RUBEN A · officer: General Counsel | Purchase | 40,000 | $0.33 |
| Dec 12, 2025 | GARCIA RUBEN A · officer: General Counsel | Purchase | 140,000 | $0.34 |
| Jun 12, 2025 | Niklas Victoria Ninon Olivia · director | A-Award | 22,000 | $0.87 |
| Jun 12, 2025 | Cilento Richard C. Jr. · director | A-Award | 22,000 | $0.87 |
| Jun 12, 2025 | Coen Stacy Ann · director | A-Award | 22,000 | $0.87 |
| Jun 12, 2025 | Hoffman Robert E. · director | A-Award | 22,000 | $0.87 |
| Jun 12, 2025 | Link Matthew · director | A-Award | 22,000 | $0.87 |
| Jun 10, 2025 | Davis Jason · officer: Chief Financial Officer | A-Award | 450,000 | $0.94 |
| May 27, 2025 | Khoja Hamid · officer: Chief Scientific Officer | Purchase | 20,000 | $0.84 |
| Mar 28, 2025 | O'HEERON PETE · director, officer: CHIEF EXECUTIVE OFFICER | A-Award | 453,000 | $1.04 |
| Mar 28, 2025 | Khoja Hamid · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 189,000 | $1.04 |
| Mar 28, 2025 | GARCIA RUBEN A · officer: General Counsel | A-Award | 189,000 | $1.04 |
| Dec 30, 2024 | O'HEERON PETE · director, officer: Chief Executive Officer | A-Award | 406,339 | $2.36 |
| Dec 30, 2024 | GARCIA RUBEN A · officer: General Counsel | A-Award | 176,200 | $2.36 |
| Dec 30, 2024 | Khoja Hamid · officer: CHIEF SCIENTIFIC OFFICER | A-Award | 176,200 | $2.36 |
Institutional positioning
13F filings over the trailing two quarters
New 8Increased 5Reduced 17Sold out 5
| Filer | Action | Shares | Filed |
|---|---|---|---|
| Cascade Financial Partners, LLC | Increased | 108,828 | Aug 4, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 67,665 | May 15, 2026 |
| Fund Evaluation Group, LLC | Unchanged | 51,794 | Aug 7, 2026 |
| FUND EVALUATION GROUP, LLC | New Position | 51,794 | May 8, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 30,299 | Aug 12, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Reduced | 29,609 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Reduced | 27,769 | Aug 13, 2026 |
| BLACKROCK, INC. | Reduced | 24,647 | May 13, 2026 |
| Qube Research & Technologies Ltd | New Position | 24,313 | Aug 14, 2026 |
| BlackRock, Inc. | Reduced | 18,238 | Aug 7, 2026 |
| CASCADE FINANCIAL PARTNERS, LLC | Reduced | 16,428 | May 12, 2026 |
| RENAISSANCE TECHNOLOGIES LLC | Reduced | 15,997 | May 14, 2026 |
| GOLDMAN SACHS GROUP INC | Unchanged | 10,468 | Mar 25, 2026 |
| BARCLAYS PLC | New Position | 7,243 | Aug 14, 2026 |
| VANGUARD FIDUCIARY TRUST CO | Unchanged | 6,380 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 15, 2026